Search Results

You are looking at 51 - 55 of 55 items for :

  • "hepatitis B virus" x
  • Refine by Access: All x
Clear All
Full access

Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Oxana V. Crysler, Neel Gupta, Chelsea Gustafson, Allison Hall, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Julian Sanchez, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Sai Yendamuri, Mary A. Dwyer, CGC, and Deborah A. Freedman-Cass

dysregulation and coinfection with viruses such as human papillomavirus, human herpesvirus 8 (HHV-8), hepatitis B virus, hepatitis C virus, and Epstein-Barr virus. 12 – 16 In addition, the prevalence of other cancer risk factors in the HIV-positive population

Full access

Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Neel Gupta, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Oxana V. Makarova-Rusher, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Frank Palella, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Mary A. Dwyer, and Deborah A. Freedman-Cass

immune deficiency and coinfection with viruses such as human papillomavirus (HPV), human herpesvirus 8, hepatitis B virus, hepatitis C virus, and Epstein-Barr virus. 14 – 18 In addition, the prevalence of other cancer risk factors in the HIV population

Full access

patients were treated: median age, 70 years (range, 56–82); male, 56%; hepatitis B virus, 33%; hepatitis C virus, 0%; Child Pugh A, 100%; prior sorafenib, 100%; 6 patients in the dose-finding cohort, 3 in the expansion cohort; all patients received ENZA

Full access

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Matthew Lunning, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar

page 199). Patients with high tumor burden and elevated serum lactate dehydrogenase (LDH) should be assessed for spontaneous tumor lysis syndrome, including measurements of uric acid, potassium, phosphorous, calcium, and renal function. Hepatitis B

Full access

Shaji K. Kumar, Natalie S. Callander, Kehinde Adekola, Larry Anderson, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, Jason C. Chandler, Caitlin Costello, Yvonne Efebera, Matthew Faiman, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Yubin Kang, Malin Hultcrantz, Sarah Larson, Michaela Liedtke, Thomas Martin, James Omel, Kenneth Shain, Douglas Sborov, Keith Stockerl-Goldstein, Donna Weber, Jennifer Keller, and Rashmi Kumar

hepatitis B virus is a complication in patients receiving carfilzomib or daratumumab. Therefore, testing for hepatitis B in these patients is recommended. Pneumocystis jiroveci pneumonia, herpes zoster, and antifungal prophylaxis is recommended if high